LAC-HYDRIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lac-hydrin, and what generic alternatives are available?
Lac-hydrin is a drug marketed by Sun Pharm Inds Inc and is included in two NDAs.
The generic ingredient in LAC-HYDRIN is ammonium lactate. There are forty drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the ammonium lactate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lac-hydrin
A generic version of LAC-HYDRIN was approved as ammonium lactate by PADAGIS ISRAEL on May 1st, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LAC-HYDRIN?
- What are the global sales for LAC-HYDRIN?
- What is Average Wholesale Price for LAC-HYDRIN?
Summary for LAC-HYDRIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 39 |
| Clinical Trials: | 2 |
| Patent Applications: | 1,047 |
| DailyMed Link: | LAC-HYDRIN at DailyMed |
Recent Clinical Trials for LAC-HYDRIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of California, San Francisco | Phase 4 |
| Icahn School of Medicine at Mount Sinai | Phase 4 |
US Patents and Regulatory Information for LAC-HYDRIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | LAC-HYDRIN | ammonium lactate | CREAM;TOPICAL | 020508-001 | Aug 29, 1996 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Sun Pharm Inds Inc | LAC-HYDRIN | ammonium lactate | LOTION;TOPICAL | 019155-001 | Apr 24, 1985 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LAC-HYDRIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | LAC-HYDRIN | ammonium lactate | LOTION;TOPICAL | 019155-001 | Apr 24, 1985 | 4,105,783 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LAC-HYDRIN
See the table below for patents covering LAC-HYDRIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 2740349 | ⤷ Subscribe | |
| Hong Kong | 46285 | COSMETIC COMPOSITIONS FOR THE TREATMENT OF DRY SKIN | ⤷ Subscribe |
| Portugal | 67007 | METHOD FOR TREATING DRY SKIN | ⤷ Subscribe |
| Japan | H0231053 | ⤷ Subscribe | |
| Australia | 519802 | ⤷ Subscribe | |
| Belgium | 858404 | ⤷ Subscribe | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LAC-HYDRIN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0496835 | C960031 | Netherlands | ⤷ Subscribe | PRODUCT NAME: DOXORUBICINESULFAAT VERKREGEN UIT DOXORUBICINEHYDROCHLORIDE EN AMMONIUMSULFAAT; REGISTRATION NO/DATE: EU/1/96/011/001 - EU/1/96/011/002 19960621 |
| 0230893 | C980024 | Netherlands | ⤷ Subscribe | PRODUCT NAME: GADOBEENZUUR,DESGEWENST IN DE VORM VAN EEN ZOUT MET EEN ALKA- LIMETAAL, AARDALKALIMETAAL, OF BASISCH GEPROTONEERD AMINOZUUR OF VAN EEN ALKYLAMMONIUM-, ALKANOLAMMONIUM- OF POLYHYDROXYAL- KYLAMMONIUMZOUT, IN HET BIJZONDER DIMEGLUMINI GADOBENAS; NAT. REGISTRATION NO/DATE: RVG 22324 19980706; FIRST REGISTRATION: GB PL 06099/0006 19970722 |
| 0266730 | SPC/GB97/005 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: DOLASETRON, OR A PHARMACEUTICALLY-ACCEPTABLE ACID ADDITION OR QUATERNARY AMMONIUM SALT THEREOF; REGISTERED: UK 04425/0150 19960926 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
